Intracellular metabolism of the orally active platinum drug JM216: Influence of glutathione levels

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 380-386

  Raynaud, F I ^a   Odell, D E ^a   Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Glutathione; JM216; Metabolism; Platinum

Indexed keywords

BUTHIONINE SULFOXIMINE; GLUTATHIONE; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; SATRAPLATIN;

ARTICLE; CELL GROWTH; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PLASMA; PRIORITY JOURNAL;

EID: 0030055978     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.369     Document Type: Article

References (45)

1. ALI-OSMAN F AND RAIRKAR A. (1992). Alterations in DNA polymerases a, b and d in human brain tumor cells after glutathione depletion (abstract). Proc. Am. Assoc. Cancer Res., 33, 497.
2. ANDREWS PA AND HOWELL SB. (1990). Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2, 35 43.
3. ANDREWS PA, MURPHY MP AND HOWELL SB. (1985). Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res., 45, 6250-6253.
4. ANDREWS PA, SCHIEFFER MA, MURPHY MP AND HOWELL SB. (1988). Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by prolonged glutathione depletion. Chem. Biol. Interact., 65, 51-58.
5. BATIST G, BEHRENS, BC, MAKUCH, R., HAMILTON TC, KATKI AG, LOUIE KG, MYERS CE AND OZOLS RF. (1986). Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. Biochem. Pharmacol., 35, 2257-2259.
6. EASTMAN A. (1987a). Glutathione-mediated activation of anticancer platinum IV complexes. Biochem. Pharmacol., 36, 4177-4178.
7. EASTMAN A. (1987b). The formation, isolation and characterisation of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther., 34, 155-166.
8. GIANDOMENICO CM, ABRAMS MJ, MURRER BA, VOLLANO JF, BARNARD CFJ, HARRAP KR, GODDARD PM, KELLAND LR AND MORGAN SE. (1991). Synthesis and reactions of a new class of orally active Pt(IV) antitumor complexes. In Platinum and other Metal Coordination Compounds in Cancer Chemotherapy. Howell SB (ed.) pp. 93-100. Plenum Press: New York.
9. GIBBONS GP, WYRICK S AND CHANEY SG. (1989). Rapid reduction of tetrachloro (D,L-trans) 1-2, diaminocyclohexane platinum IV (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res., 49, 1402-1407.
10. GRIFFITHS OW. (1980). Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinyl pyridine. Anal. Biochem., 106, 207-211.
11. HILLS CA, KELLAND LR, ABEL G, SIRACKY J, WILSON AP AND HARRAP KR. (1989). Biological properties of ten human carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527-534.
12. HOSKINGLK, WHELAN RD, SHELLARD SA, BEDFORD P AND HILL BT. (1990). An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. Biochem. Pharmacol., 40, 1833-1842.
13. ISHIKAWA T AND ALI-OSMAN F. (1993). Glutathione- associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem., 268, 20116-20125.
14. ISHIKAWA T, WRIGHT CD AND ISHIZUKA H. (1994). GS-X Pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down regulated by cell differentiation. J. Biol. Chem., 269, 29085-29093.
15. KELLAND LR, MURRER BA, ABEL G, GIANDOMENICO CM, MISTRY P AND HARRAP KR. (1992). Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian cell lines. Cancer Res., 52, 822-828.
16. KELLAND LR, ABEL G, MCKEAGE MJ, JONES M, GODDARD PM, VALENTI M, MURRER BA AND HARRAP KR. (1993). Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res., 53, 2581-2586.
17. LEWIS AD, HAYES JD AND WOLF CR. (1988). Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. Carcinogenesis, 9, 1283-1287.
18. LOH SY, MISTRY P, KELLAND LR, ABEL G AND HARRAP KR. (1992). Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br. J. Cancer, 66, 1109-1115.
19. LOWRY OH, ROSENBROUGH MT, FARR AL AND RANDALL RJ. (1951). Protein measurements with the folin phenol reagent. J. Biol. Chem., 193, 265-269.
20. MCKEAGE MJ, MORGAN SE, BOXALL FE, MURRER BA, HARD GC AND HARRAP KR. (1993). Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br. J. Cancer, 67, 996-1000.
21. MCKEAGE MJ, BOXALL FE, JONES M, HARRAP KR. (1994a). Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. Cancer Res., 54, 629-631.
22. MCKEAGE MJ, KELLAND LR, BOXALL FE, VALENTI MR, JONES M, GODDARD PM, GWYNNE J AND HARRAP KR. (1994b). Schedule dependency of orally administered bisacetatoamminedichlorocyclohexylamine-platinum(IV) (JM216) in vivo. Cancer Res., 54, 4118-4122.
23. MCKEAGE MJ, RAYNAUD FI, WARD J, BERRY C, ODELL D, MISTRY P, KELLAND LR, MURRER BA, SANTABARBARA P, HARRAP KR AND JUSDON IR. (1994c). Phase I study of an orally administered platinum complex (JM216) using a daily × 5 administration schedule (abstract). Proc. Amer Soc. Clin. Oncol., 13, 337.
24. MCKEAGE MJ, MISTRY P, WARD J, BOXALL FE, LOH S, O'NEILL C, ELLIS P, KELLAND LR, MORGAN SE, MURRER BA, SANTABARBARA P, HARRAP KR AND JUDSON IR. (1995). Phase I and pharmacological study of an oral platinum complex (JM216): dose dependent pharmacokinetics with single dose administration. Cancer Chemother. Pharmacol., 36, 451-458.
25. MASUDA H, OZOLS RF, LAI GM, FOJO A, ROTHENBERG M AND HAMILTON TC. (1988). Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res., 48, 5713 5716.
26. MEIJER C, MULDER NH, TIMMER-BOSSCHA H, SLUITER WJ, MEERSMA GJ AND DE VRIES EGE. (1992). Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res., 52, 6885-6889.
27. MELLISH KJ AND KELLAND LR. (1994). Mechanisms of acquired resistance to the orally active platinum-based anticancer drug, JM216, [Bis acetato-ammine dichloro cyclohexylamine platinum(IV)] in two human ovarian carcinoma cell lines. Cancer Res., 54, 6194-6200.
28. MELLISH KJ, KELLAND LR AND HARRAP KR. (1993). In vitro platinum drug sensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br. J. Cancer, 68, 240-250.
29. MELLISH KJ, BARNARD CFJ, MURRER BA AND KELLAND LR. (1995). DNA-binding properties of novel cis- and trans platinum based anticancer agents in two human ovarian carcinoma cell lines. Int. J. Cancer, 62, 717-723.
30. MISTRY P., KELLAND LR, ABEL G, SIDHAR S AND HARRAP KR (1991). The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer, 64, 215-220.
31. MISTRY P, LOH SY, KELLAND LR AND HARRAP KR. (1993). Effect of buthionine sulfoximine on Pt(II) and Pt(IV)-drug accumulation and the formation of glutathione conjugates in human ovarian carcinoma cell lines. Int. J. Cancer, 55, 848-856.
32. MULLER M, MEIJER C, ZAMAN GJR, BORST P, SCHEPER RJ, MULDER NH, DE-VRIES EGE AND JANSEN PLM. (1994). Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl Acad. Sci. USA, 91, 13033-13037.
33. NOVAKOVA O, VRANA O, KISELEVA VI AND BRABEC V. (1995). DNA interactions of antitumour platinum IV complexes. Eur. J. Biochem., 228, 616-624.
34. ORR RM, O'NEILL CF, NICHOLSON MC, BARNARD CFJ, MURRER BA, GIANDOMENICO CM, VOLLANO JF AND HARRAP KR. (1994). Evaluation of novel ammine/amine platinum(IV) dicarboxylates in L 1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br. J. Cancer, 70, 415 420.
35. PENDYALA L, WALSH JR, HUQ MM, ARAKALI AV, COWENS JW AND CREAVEN PJ. (1989). Uptake and metabolism of Iproplatin in murine L1210 cells. Cancer Chemother. Pharmacol., 25, 15-18.
36. PENDYALA L, CREAVEN PJ, PEREZ R, ZDANOWICZ JR AND RAGHAVAN D. (1995). Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 36, 271 278.
37. POON GK, RAYNAUD FI, MISTRY P, ODELL DE, KELLAND LR, HARRAP KR, BARNARD CFJ AND MURRER BA. (1995). Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionisation-mass spectrometry. J. Chromatogr., 712, 61-66.
38. POST GB, KELLER DA, CONNOR KA AND MENZEL DB. (1983). Effect of culture conditions on glutathione content in A549 cells. Biochem. Biophys. Res. Commun., 114, 737-742.
39. RAIRKAR A AND ALI-OSMAN F. (1992). Modulation of DNA ligase activities in a BCNU and cisplatin (CDDP) resistant human malignant astrocytoma cell line by glutathione (GSH) depletion (abstract). Proc. Am. Assoc. Cancer Res., 33, 7.
40. RAYNAUD FI, MCKEAGE MJ, WARD J, BERRY C, ODELL D, MURRER BA, SANTABARBARA P, JUDSON IR AND HARRAP KR. (1995). Pharmacokinetic study of orally administered ammine diacetato dichloro (cyclohexylamine) platinum (IV) (JM216) in a 5-day dose schedule Phase I clinical trial. In Novel Approaches in Anticancer Drug design. Molecular Modelling and New Treatment Strategies. Zeller WJ, D'Indalci M and Newell DR (eds). pp. 100-108. Karger: Basle.
41. RAYNAUD FI, MISTRY P, DONAGHUE A, POON GK, KELLAND LR, BARNARD CFJ, MURRER BA AND HARRAP KR. (1996). Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother. Pharmacol. (in press).
42. RICHON VM, SCHULTE N AND EASTMAN A. (1987). Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res., 47, 2056-2061.
43. SHARP SY, ROGERS P AND KELLAND LR. (1995). Transport of cisplatin and bis-acetato-ammine dichlorocyclohexylamine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin. Cancer Res., 1, 981-989.
44. TWENTYMAN PR, WRIGHT KA, MISTRY PA, KELLAND LR AND MURRER BA. (1992). Sensitivity to novel platinum compounds in panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res., 52, 5674-5680.
45. VERSANTVOORT CHM, BROXTERMAN HJ, BAGRIJ T, SCHEPER RJ AND TWENTYMAN PR. (1995). Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br. J. Cancer, 72, 82-89.